These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35335040)

  • 21. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021.
    Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N
    JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
    Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis.
    Salmon DA; Proschan M; Forshee R; Gargiullo P; Bleser W; Burwen DR; Cunningham F; Garman P; Greene SK; Lee GM; Vellozzi C; Yih WK; Gellin B; Lurie N;
    Lancet; 2013 Apr; 381(9876):1461-8. PubMed ID: 23498095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports.
    Guo W; Deguise J; Tian Y; Huang PC; Goru R; Yang Q; Peng S; Zhang L; Zhao L; Xie J; He Y
    Front Pharmacol; 2022; 13():870599. PubMed ID: 35814246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system.
    Chen C; Fu F; Ding L; Fang J; Xiao J
    Front Immunol; 2022; 13():938322. PubMed ID: 36172346
    [TBL] [Abstract][Full Text] [Related]